Revolution Ventures

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel therapies that inhibit frontier targets within the RAS pathway, one of the most common drivers of human cancer. The company's proprietary platform is designed to identify and develop "RAS(ON)" inhibitors, which specifically target the active, GTP-bound form of RAS proteins. Their lead candidate, RMC-6236, is a first-in-class multi-RAS(ON) inhibitor currently in late-stage clinical development for pancreatic and lung cancers. By targeting the active state of the protein, Revolution Medicines aims to provide more comprehensive and durable responses for patients with a wide range of RAS mutations compared to first-generation inhibitors.